(Reuters) - LONDON, July 27 - GlaxoSmithKline Plc took
a further step to boost its new drug pipeline on Friday by
clinching a drug development deal potentially worth more than
$1.5 billion with U.S. biotech firm Targacept Inc. .
The alliance gives Europe's biggest drugmaker access to
Targacept's neuronal nicotinic receptor compounds, including an
experimental drug in mid-stage Phase II clinical trials for
acute post-operative pain.
Read more at Reuters.com Mergers News
a further step to boost its new drug pipeline on Friday by
clinching a drug development deal potentially worth more than
$1.5 billion with U.S. biotech firm Targacept Inc. .
The alliance gives Europe's biggest drugmaker access to
Targacept's neuronal nicotinic receptor compounds, including an
experimental drug in mid-stage Phase II clinical trials for
acute post-operative pain.
Read more at Reuters.com Mergers News
No comments:
Post a Comment